Published in J Clin Oncol on May 01, 1998
Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer (2000) 1.57
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer (2000) 1.07
A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug. Invest New Drugs (1999) 0.93
The frequency and severity of capecitabine-induced hypertriglyceridaemia in routine clinical practice: a prospective study. Br J Cancer (2010) 0.93
Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. Br J Cancer (2004) 0.93
The oral fluorinated pyrimidines. Invest New Drugs (2001) 0.92
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. Br J Cancer (2009) 0.91
Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report. Korean J Intern Med (2007) 0.90
A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer. Clin Cancer Res (2008) 0.89
Impact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesis. Br J Cancer (2001) 0.88
Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer (2000) 0.87
Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer. Br J Cancer (2003) 0.86
Targeting cancers in the gastrointestinal tract: role of capecitabine. Onco Targets Ther (2009) 0.85
Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling. Breast Dis (2010) 0.84
Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience. Invest New Drugs (2003) 0.84
Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients. J Cancer Res Clin Oncol (2011) 0.83
A case of capecitabine-induced coronary microspasm in a patient with rectal cancer. World J Gastroenterol (2007) 0.83
The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery. Invest New Drugs (2000) 0.83
Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane. J Korean Med Sci (2004) 0.82
A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer. Br J Cancer (2007) 0.82
Simulations to Assess Phase II Noninferiority Trials of Different Doses of Capecitabine in Combination With Docetaxel for Metastatic Breast Cancer. CPT Pharmacometrics Syst Pharmacol (2012) 0.80
Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials. Br J Clin Pharmacol (2014) 0.80
A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. Cancer Chemother Pharmacol (2014) 0.80
A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors. Anticancer Res (2010) 0.80
An epigenetic mechanism for capecitabine resistance in mesothelioma. Biochem Biophys Res Commun (2009) 0.80
Chemotherapy with low-dose capecitabine as palliative treatment in a patient with metastatic breast cancer: a case report. Cases J (2009) 0.79
Capecitabine for locally advanced and metastatic colorectal cancer: A review. World J Gastrointest Oncol (2010) 0.79
A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer. Br J Cancer (2003) 0.78
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine. Cancer Chemother Pharmacol (2008) 0.78
Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy. Br J Clin Pharmacol (2006) 0.77
Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study. Gynecol Oncol (2006) 0.77
Capecitabine. Invest New Drugs (2000) 0.77
Timing of significant adverse events is essential information during early development of new drugs. Int J Clin Oncol (2006) 0.75
Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer. Br J Cancer (2001) 0.75
Effects of capecitabine treatment on the uptake of thymidine analogs using exploratory PET imaging agents: (18)F-FAU, (18)F-FMAU, and (18)F-FLT. Cancer Imaging (2016) 0.75
Pilot study investigating the prognostic significance of thymidine phosphorylase expression in patients with metastatic breast cancer: a single institution retrospective analysis. Onco Targets Ther (2015) 0.75
Capecitabine: an evidence-based review of its effectiveness in the treatment of carcinoma of the pancreas. Core Evid (2007) 0.75
Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer? Br J Cancer (2002) 0.75
Capecitabine plus Cisplatin treatment for advanced gastric cancer in a patient with hepatic impairment secondary to metastases. Gastrointest Cancer Res (2012) 0.75
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood (1999) 11.57
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol (2001) 5.25
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol (2001) 4.89
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol (1999) 3.62
Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin. Antimicrob Agents Chemother (1981) 3.50
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol (2001) 3.21
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol (2000) 3.04
Ambulatory care sensitive conditions: terminology and disease coding need to be more specific to aid policy makers and clinicians. Public Health (2009) 2.90
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol (2002) 2.87
Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol (2009) 2.74
A fluorimetric study of the hydroxylation of biphenyl in vitro by liver preparations of various species. Biochem J (1965) 2.47
Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J Exp Med (1989) 2.16
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol (1999) 2.03
The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res (2001) 2.01
Patterns of breast carcinoma treatment in older women: patient preference and clinical and physical influences. Cancer (2000) 1.97
Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer (2001) 1.96
Cytochrome c oxidase: structure and spectroscopy. Annu Rev Biophys Biomol Struct (1998) 1.92
Constructs of burden of illness in older patients with breast cancer: a comparison of measurement methods. Health Serv Res (2001) 1.89
Elevated levels of interleukin-8 and transforming growth factor-beta in bronchoalveolar lavage fluid from patients with bronchiolitis obliterans syndrome: proinflammatory role of bronchial epithelial cells. Munich Lung Transplant Group. Transplantation (2000) 1.84
Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J (2006) 1.84
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol (2000) 1.77
A spectrofluorimetric study of the 7-hydroxylation of coumarin by liver microsomes. Biochem J (1965) 1.76
Cell size of alveolar macrophages: an interspecies comparison. Environ Health Perspect (1997) 1.71
Coexistence of Lambert-Eaton myasthenic syndrome and subacute cerebellar degeneration: differential effects of treatment. Neurology (1991) 1.66
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol (1998) 1.61
Between joy and sorrow: being a parent of a child with developmental disability. J Adv Nurs (2001) 1.59
Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res (1999) 1.57
Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med (2000) 1.57
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol (2000) 1.56
Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study. J Clin Oncol (1996) 1.54
Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer (2001) 1.52
Usefulness of exhaled nitric oxide to guide risk stratification for bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant (2010) 1.52
Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg (2001) 1.50
The fluorescence of some biphenyl derivatives. Biochem J (1965) 1.47
Impact of quality of life on patient expectations regarding phase I clinical trials. J Clin Oncol (2000) 1.47
Patient expectations of benefit from phase I clinical trials: linguistic considerations in diagnosing a therapeutic misconception. Theor Med Bioeth (2003) 1.46
Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol (2001) 1.46
Fenfluramine blocks low-Mg2+-induced epileptiform activity in rat entorhinal cortex. Epilepsia (2000) 1.42
Measuring and predicting surgeons' practice styles for breast cancer treatment in older women. Med Care (2001) 1.38
In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res (1993) 1.37
Treatment of advanced emphysema with emphysematous lung sealant (AeriSeal®). Respiration (2011) 1.33
Role of low Km cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea pig. J Pharmacol Exp Ther (1989) 1.33
Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep (1972) 1.32
Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep (1977) 1.29
Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J (2010) 1.28
Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys (1981) 1.28
Direct evidence for a tyrosine radical in the reaction of cytochrome c oxidase with hydrogen peroxide. Biochemistry (1999) 1.26
Emergency admissions for coronary heart disease: a cross-sectional study of general practice, population and hospital factors in England. Public Health (2010) 1.25
Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer (2002) 1.24
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Lung cancer and air pollution in southcentral Los Angeles County. Am J Epidemiol (1975) 1.22
Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res (1998) 1.21
Analysis of neutron radiotherapy treatment complications. Bull Cancer (1986) 1.20
Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at √s = 7 TeV. Phys Rev Lett (2012) 1.19
Azimuthal anisotropy of charged particles at high transverse momenta in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2012) 1.19
Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgG+ CD5+ chronic lymphocytic leukemia B cells. J Exp Med (1995) 1.17
Treatment of severe aplastic anaemia with antilymphocyte globulin or bone-marrow transplantation. Br Med J (Clin Res Ed) (1981) 1.16
Pulmonary function and health-related quality of life in a sample of long-term survivors of the acute respiratory distress syndrome. Intensive Care Med (2000) 1.16
Entorhinal cortex entrains epileptiform activity in CA1 in pilocarpine-treated rats. Neurobiol Dis (2005) 1.16
Familial pancreatic adenocarcinoma in three generations. A case report and a review of the literature. Cancer (1987) 1.14
Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. Cancer Res (1982) 1.14
Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis. Eur Respir J (2007) 1.13
Pharmacokinetic and pharmacodynamic studies of N-acetylcysteine, a potential chemopreventive agent during a phase I trial. Cancer Epidemiol Biomarkers Prev (1995) 1.12
Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer (1995) 1.12
Comparing different types of performance feedback and computer-based instruction in teaching medical students how to diagnose acute abdominal pain. Acad Med (1993) 1.10
Search for a W' or techni-ρ decaying into WZ in pp Collisions at sqrt[s] = 7 TeV. Phys Rev Lett (2012) 1.10
Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets in chronic lymphocytic leukemia. J Immunol (1997) 1.10
Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events. Br J Cancer (2009) 1.09
The stimulation of hydroxylation by carcinogenic and non-carcinogenic compounds. Biochem Pharmacol (1966) 1.09
Search for new physics with same-sign isolated dilepton events with jets and missing transverse energy. Phys Rev Lett (2012) 1.09
The effect of malpractice liability on the delivery of rural obstetrical care. J Rural Health (1987) 1.09
Metabolism of tyramine-1-14C by the rat. Biochem Pharmacol (1970) 1.09
End-of-life care in hospital: a descriptive study of all inpatient deaths in 1 year. Palliat Med (2009) 1.08
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer (2000) 1.07
'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study Group. Ann Oncol (1996) 1.07
[Multimorbidity and successful aging: the population-based KORA-Age study]. Z Gerontol Geriatr (2011) 1.05
A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin Cancer Res (1998) 1.05
Involvement of glutamic acid 278 in the redox reaction of the cytochrome c oxidase from Paracoccus denitrificans investigated by FTIR spectroscopy. Biochemistry (1998) 1.05
Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer. Invest New Drugs (1996) 1.05
Measurement of the Υ1S, Υ2S, and Υ3S polarizations in pp collisions at sqrt[s] = 7 TeV. Phys Rev Lett (2013) 1.05
Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations. Clin Pharmacokinet (1999) 1.04
Measurement of pulmonary parenchymal attenuation: use of spirometric gating with quantitative CT. Radiology (1990) 1.03
Treatment of acute nonlymphocytic leukemia: use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens. Blood (1979) 1.03
Oral tramadol, a mu-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer-related pain. Ann Oncol (1994) 1.03
Spacer arms in affinity chromatography: use of hydrophilic arms to control or eliminate nonbiospecific adsorption effects. FEBS Lett (1974) 1.02
Ethanol oxidation in the microsomal fraction of rat liver. Biochem Biophys Res Commun (1969) 1.02
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. J Clin Oncol (1999) 1.02
Glutamate-cysteine ligase modulatory subunit in BAL alveolar macrophages of healthy smokers. Eur Respir J (2003) 1.02
Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol (2007) 1.02